● Recruiting

Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.

Condition: Ankylosing Spondylitis · Sponsor: Novartis Pharmaceuticals

PhaseN/A

Planned participants70

Who can joinAll sexes, 18 Years to 40 Years

Healthy volunteersNo

About this study

This is an observational study to evaluate the effectiveness and safety of secukinumab in participants with AS who have never used TNFi, JAKi, or IL-17i drugs before.

This description comes directly from the study's public registry record.

Talk to the study team

Novartis Pharmaceuticals, MD · +41613241111 · thomas.paul@novartis.com

Novartis Pharmaceuticals · minsoo.jee@novartis.com

Always discuss trial participation with your own doctor first.

Locations (2)

Novartis Investigative Site	Jinju, Gyeongsangnam-do, South Korea	Recruiting
Novartis Investigative Site	Busan, South Korea	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06905288